JADE101
Stories
-
Jade Biosciences registers Phase 3 study of JADE101 in IgA nephropathy
The study, titled the EVERGREEN STUDY, plans to enroll 480 participants and has a planned start date of December 2026. It will evaluate the safety and efficacy of JADE101 versus placebo in adults with immunoglobulin A nephropathy.